No. S 194

MISUSE OF DRUGS ACT
(CHAPTER 185)

MISUSE OF DRUGS ACT (AMENDMENT OF FIRST AND FIFTH SCHEDULES) ORDER 2017

In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:

Citation and commencement

1. This Order is the Misuse of Drugs Act (Amendment of First and Fifth Schedules) Order 2017 and comes into operation on 1 May 2017.

Amendment of Part I of First Schedule

2. Part I of the First Schedule to the Misuse of Drugs Act is amended —

(*a*) by deleting item (8) of paragraph 1;

(*b*) by deleting item (20) of paragraph 1 and substituting the following item:

"(20) 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine (also known as 4-bromo-2,5-dimethoxyphenethylamine or 2C-B) and its bromo and dimethoxy positional isomers in the phenyl ring";

(*c*) by deleting items (44) and (45) of paragraph 1 and substituting the following items:

"(44) 2,5-Dimethoxy-4,α-dimethylphenethylamine (also known as 2-amino-1-(2,5-dimethoxy-4-methyl) phenylpropane or DOM)

(45) 2,5-Dimethoxy-α-methylphenethylamine (also known as 2,5-Dimethoxyamphetamine) and its dimethoxy positional isomers in the phenyl ring";

(*d*) by deleting item (86) of paragraph 1 and substituting the following item:

"(86) p-Methoxy-α-methylphenethylamine (also known as 4-methoxyamphetamine or para-methoxyamphetamine) and its methoxy positional isomers in the phenyl ring";

(*e*) by inserting, immediately after item (7) of paragraph 7, the following item:

"(7A) Butyryl fentanyl (also known as butyrfentanyl)";

(*f*) by deleting items (1) and (2) of paragraph 16 and substituting the following items:

"(1) 1-(1,3-Benzodioxol-5-yl)-2-(benzylamino) propan-1-one (also known as 3,4-Methylenedioxy-N-benzylcathinone or BMDP)

(1A) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-propanone (also known as bk-MDDMA)

(2) 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino) propan-1-one (also known as ethylone or 3,4-Methylenedioxy-N-ethylcathinone or bk-MDEA or MDEC)";

(*g*) by deleting item (8A) of paragraph 16 and substituting the following items:

"(8A) 2-(Benzylamino)-1-(4-methylphenyl)propan-1-one (also known as Benzedrone)

(8AA) 1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brephedrone or 4-BMC)";

(*h*) by inserting, immediately after item (8B) of paragraph 16, the following item:

"(8C) 2-(Diethylamino)-1-phenyl-1-propanone (also known as amfepramone or diethylpropion or diethylcathinone)";

(*i*) by deleting item (10A) of paragraph 16 and substituting the following items:

> "(10A) 2-(Ethylamino)-1-(4-ethylphenyl)propan-1-one (also known as 4-Ethylethcathinone)
>
> (10B) 2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC)";

(*j*) by inserting, immediately after item (17) of paragraph 16, the following item:

> "(17A) 2-(Methylamino)-1-(4-methylphenyl)butan-1-one (also known as 4-Methylbuphedrone or 4-Me-MABP)";

(*k*) by deleting item (19) of paragraph 16 and substituting the following item:

> "(19) 2-(Methylamino)-1-phenylpentan-1-one (also known as pentedrone or α-Methylaminovalerophenone)";

(*l*) by inserting, immediately after item (22) of paragraph 16, the following item:

> "(22A) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Methyl-α-pyrrolidinohexanophenone or MPHP)";

(*m*) by inserting, immediately after item (23) of paragraph 16, the following item:

> "(23A) 1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as 4-Methyl-α-pyrrolidinopropiophenone or 4-MePPP)";

(*n*) by deleting item (2B) of paragraph 18 and substituting the following item:

> "(2B) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as MAB-CHMINACA or ADB-CHMINACA)";

(*o*) by deleting items (2J) and (2K) of paragraph 18 and substituting the following items:

> "(2J) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also